Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Ranibizumab (Lucentis; Genentech), a humanized monoclonal antibody fragment that binds to vascular endothelial growth factor, was approved by the US FDA in June 2006 for the treatment of patients with neovascular age-related macular degeneration.